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OBJECTIVE
Infants born to mothers with gestational diabetes mellitus (GDM) are at greater
risk of later adverse metabolic health. We examined plausible candidate media-
tors; adipose tissue (AT) quantity and distribution, and intrahepatocellular lipid
(IHCL) content, comparing infants of mothers with GDM and without GDM (con-
trol group) over the ﬁrst 3 postnatal months.
RESEARCH DESIGN AND METHODS
We conducted a prospective longitudinal study using MRI and spectroscopy to
quantify whole-body and regional AT volumes, and IHCL content, within 2 weeks
and 8–12 weeks after birth. We adjusted for infant size and sex, and maternal
prepregnancy BMI. Values are reported as the mean difference (95% CI).
RESULTS
We recruited 86 infants (GDMgroup 42 infants; control group 44 infantsQ:1 ).Mothers
with GDM had good pregnancy glycemic control. Infants were predominantly
breast fed up to the time of the second assessment (GDM group 71%; control
group 74%). Total AT volumes were similar in the GDM group compared with the
control group at amedian age of 11 days (228 cm3 [95%CI2121, 65], P = 0.55), but
were greater in the GDMgroup at amedian age of 10weeks (247 cm3 [56, 439], P =
0.01). After adjustment for size, the GDM group had signiﬁcantly greater total AT
volume at 10 weeks than control group infants (16.0% [6.0, 27.1], P = 0.002). AT
distribution and IHCL content were not signiﬁcantly different at either time point.
CONCLUSIONS
Adiposity in GDM infants is ampliﬁed in early infancy, despite good maternal
glycemic control and predominant breast-feeding, suggesting a potential causal
pathway to later adverse metabolic health. Reduction in postnatal adiposity may
be a therapeutic target to reduce later health risks.
Diabetes in pregnancy is increasing and currently affects up to 5% of women in the
U.K. (1), and up to 9.2% in the U.S. (2). Approximately 87.5% of cases are gestational
diabetes mellitus (GDM), 7.5% are type 1 diabetes, and 5% are type 2 diabetes (1).
The offspring of mothers with diabetes have greater risks of adverse metabolic
sequelae in childhood and later life that appear to be additional to genetic pre-
disposition (3–5).
The underlying mechanisms are unclear, but increased infant adiposity is a plau-
sible mediator because adiposity in childhood and adult life are associated with
type 2 diabetes and cardiovascular disease (6). The Hyperglycemia and Adverse
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Pregnancy Outcome (HAPO) study iden-
tiﬁed a strong association between
maternal glycemia and anthropometry-
derived adiposity in newborn infants (7).
The ﬁrst 3 months of life is a critical pe-
riod for adipose tissue (AT) deposition
(8), but, to our knowledge, longitudinal
examination of the quantity and distri-
bution of AT in early infancy has not
been undertaken in the offspring of
mothers with diabetes.
Internal abdominal AT is associated
with higher metabolic risk (9), whereas
abdominal or nonabdominal superﬁcial
subcutaneous AT may be protective
(10). Indirect body composition tech-
niques require assumptions to enable
the calculation of fat mass, and although
they may provide an indication of fat
mass distribution, they are unable to dif-
ferentiate individual AT compartments.
We aimed to examine total and re-
gional AT volumes using a direct tech-
nique, whole-body MRI, soon after
birth and again in later infancy, in a pro-
spective cohort of infants with GDM and
control infants. Intrahepatocellular lipid
(IHCL) content has a strong association
with internal abdominal AT and may be
more closely linked with adverse meta-
bolic outcomes (11), and, because non-
alcoholic fatty liver disease is now the
most common form of chronic liver dis-
ease in children (12), we also aimed to
compare IHCL content.
RESEARCH DESIGN AND METHODS
We recruited healthy, full-term (37–42
weeks) infants with GDM and control
infants from the postnatal wards at
Chelsea and Westminster Hospital, Lon-
don, U.K., between October 2011 and
October 2014. This is a major teaching
hospital, with ;6,000 births each year.
We endeavored to approach all mothers
with GDM and similar numbers of con-
trol subjects. We used no additional se-
lection criteria, and recruited in keeping
with the availability of the MRI scanner.
We excluded mothers with pre-existing
diabetes and small for gestational age
infants because we have previously
shown them to have altered AT distribu-
tion (13). We undertook assessments at
the following two time points: within 2
weeks of birth and at 8–12 weeks after
birthQ:2 . If the initial scanwas unsuccessful,
the infant did not continue in the study.
The study received approval from the
National Research Ethics Committee
(reference 11/LO/1167), and informed,
written maternal consent was obtained.
Hospital policy was for all women
with risk factors for GDM to undergo a
standard 2-h 75-g oral glucose tolerance
test at 26 weeks of gestation. If the results
were normal, in women with previous
GDM this was repeated at 30 weeks. All
women without risk factors underwent a
1-h, 50-g glucose screening test at 26–
28 weeks of gestation Q:3. Those with ab-
normal screening results ($7.8 mmol/L)
then had a full oral glucose tolerance
test. GDM was diagnosed in mothers
by the obstetric team using the follow-
ing criteria: fasting plasma glucose con-
centration $5.3 mmol/L or 2-h plasma
glucose concentration $7.8 mmol/L.
Women were referred to the antenatal
diabetes clinic for dietary and exercise
advice, and were requested to monitor
premeal and postmeal blood glucose
levels. Target blood glucose levels
were ,5.5 mmol/L premeal and ,7.8
mmol/L 1 h postmeal. Metformin treat-
ment was considered in obese or se-
verely insulin-resistant women, and
insulin treatment was commenced if
blood glucose levels exceeded target
ranges.
We used maternal height recorded at
the antenatal booking and prepreg-
nancy weight obtained by maternal re-
call to calculate the prepregnancy BMI.
Recalled and measured prepregnancy
weight are highly correlated (14). We
measured infant weight, length, and oc-
cipital frontal circumference (OFC) at
the time of imaging. Weight was ob-
tained using scales (Professional Baby
Scale Q:4; Marsden, London, U.K.; precision
62 g), lengthwasmeasured using a Roll-
ametre (Raven Equipment Ltd., Dunmow,
Essex, U.K.), and OFC was recorded
using a tapemeasure (ChildGrowth Foun-
dation, London, U.K.).
We classiﬁed infant feeding as exclu-
sively or predominantly breast fed, ex-
clusively or predominantly formula fed,
or mixed fed (similar proportions of
breast milk and formula). Ethnicity was
reported by parents, and was catego-
rized as Asian, Afro-Caribbean, Cauca-
sian, African, and mixed race.
We estimated the sample size for the
primary outcome using pilot data and
simulation, based on 5% signiﬁcance,
adjusting for infant size, and allowing
for the possibility of an interaction be-
tween maternal diabetes status and
infant sex. We calculated that 42 infants
in each group would provide 80% power
to detect a mean difference between
GDM and control infants of 86 cm3
(11% difference) in total AT volume,
and 90% power to detect a difference
of 6 cm3 (38%) in the smallest of the
measured regional compartments, the
abdominal deep subcutaneous com-
partment. We considered these differ-
ences likely to be clinically relevant
because they are similar to that be-
tween preterm-at-term and healthy
term infants (15), and the former is a
group also at risk for later adverse met-
abolic health. We therefore aimed to
continue recruitment until a minimum
of 42 infants in each group had com-
pleted the ﬁrst MRI assessment.
MRI Procedures
We scanned infants in natural postpran-
dial sleep, without sedation, in accor-
dance with a protocol established
by our research group (16). Imaging
data were acquired on a 1.5-T magnet
(MAGNETOM Avanto; Siemens Medical
Systems, Erlangen, Germany) using the
integral body coil. Infants were scanned
in the supine position in the axial plane
during free breathing. Full body imaging
took ;20 min. We used a T1-weighted
fast spin echo sequence with a repeti-
tion time of 514 ms, an echo time of
11 ms, an echo train length of 3, and
three signal averages. Each slice was
5 mm thick with a 5-mm gap. The ﬁeld
of viewwas 3003 300mmwith amatrix
of 320 3 320 mm, leading to pixel sizes
of 0.93753 0.9375 mm. AT volume was
calculated for six regional depots. AT
was classiﬁed as subcutaneous or inter-
nal; subcutaneous AT was further sepa-
rated into superﬁcial or deep, and the
three compartments were divided into
abdominal (image slices from the sacrum
to the top of the liver) or nonabdominal
depots. Individual compartments were
summed to give total AT volume. We
used the following ratio to assess AT dis-
tribution; internal abdominal AT/nonab-
dominal superﬁcial subcutaneous AT. AT
area (in square centimeters) for each slice
was calculated as the sum of the pixels
multiplied by the pixel area. AT volume
(in cubic centimeters) for each slice was
calculated by multiplying the area by the
sumof the slice thickness (0.5 cm) and the
interslice distance (0.5 cm). Images were
analyzed by a single observer using a
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commercially available software program
(SliceOmatic, version 4.2; TomoVision,
Montreal, Canada), widely used in body
composition studies. This analysis was un-
dertaken independently of the investiga-
tors by the VardisGroup (London, U.K.
[www.vardisgroup.com]), and investiga-
tors were blinded to group statusQ:5 .
To measure IHCL, we acquired a
three-plane HASTEQ:6 localizer of the liver.
This ensured accurate positioning of the
voxel in the right lobe of the liver, avoid-
ing blood vessels and other tissues. We
obtained 1H magnetic resonance spec-
tra using point-resolved spectroscopy
with the following parameters: repeti-
tion time 1,500 ms, echo time 135 ms
without water suppression and with 128
signal averages, and a 153 153 15 mm
voxel sizeQ:7 . Spectra were analyzed using
the advancedmethod for accurate, robust,
and efﬁcient spectral ﬁtting (AMARES) al-
gorithm in the MRUI software package,
version 5 (17). Peak areas for water and
lipid resonances were obtained, and T1
and T2 corrections were performed
(18). Hepatic water was used as an in-
ternal standard, with results expressed
as a CH2 lipid/water ratio 3 100. Spectra
were analyzed by a single research ra-
diographer blinded to the diabetes
group.
Statistics
Data were analyzed using SPSS version
22 (IBM, Armonk, NY). Descriptive data
are presented as the mean (SD) for nor-
mally distributed data, or the median
and interquartile range where data
were non-normal. Where data were
normally distributed, independent-sam-
ple t tests were used for between-group
comparisons. For other continuous data,
t tests were applied to log-transformed
data where this was normal; otherwise,
the Mann-Whitney U test was applied
to the original data. x2 tests were used
to test for differences among categori-
cal data. We compared the following in
infants with GDM and control infants:
total and compartmental AT volumes,
AT distribution, and IHCL at each assess-
ment, and the change in total AT vol-
ume between assessments. We used
statistically optimal indices to adjust
AT volume for infant size. TheseQ:8 are AT
cubic volume/length in the neonatal pe-
riod (ﬁrst assessment) and AT square
volume/length in early infancy (second
assessment) (19). IHCL in infants is
correlated with postnatal age, but not
with infant size (20), and was adjusted
for the former. After adjustment for
size, the results are not expressed in
conventional units, and for ease of in-
terpretation, we presented the mean
percentage differences by comparing
log-transformed outcomes between
groups and exponentiating the regres-
sion coefﬁcient. Using multivariable re-
gression analysis (generalized linear
models), we also adjusted outcomes
for infant sex and maternal prepreg-
nancy BMI. To check for the violation
of regression assumptions, we assessed
standardized residuals for normality. To
further assess any possible inﬂuence of
maternal prepregnancy BMI on the as-
sociation between maternal GDM and
infant adiposity, we performed a sub-
group analysis in women with normal
prepregnancy BMI (,25 kg/m2). In or-
der to assess whether differences in
ethnicity inﬂuenced results, we also per-
formed a sensitivity analysis using data
only from Caucasian infants.
RESULTS
We approached the families of 425 in-
fants in total. Recruitment is detailed in
Fig. 1. Eighty-eight infants attended the
ﬁrst assessment; two infants did not set-
tle sufﬁciently for image acquisition.
Families were allowed time to consider
the study, and, because it was difﬁcult to
predict uptake, two additional infants
participated in the control group (i.e.,
42 infants with GDM, 44 control in-
fants). Seventy-six infants attended the
second assessment. Ten infants did not
attend because of illness (n = 4), travel
(n = 3), or the family no longer wished to
participate (n = 3). The second scan was
unsuccessful in three infants. Therefore,
complete MRI data at the ﬁrst and sec-
ond assessments were obtained for 86
and 73 infants, respectively. Spectros-
copy was performed at the end of the
MR sequence and was not obtained in a
number of babies who woke or became
restless. Spectra were available in 79 in-
fants at assessment 1 and in 51 infants
at assessment 2.
Mothers with GDM had greater pre-
pregnancy BMI than mothers with nor-
mal glucose tolerance (Table 1). The
majority of women with GDM received
medical treatment (55%), as follows:
metformin (36%), insulin (5%), or a com-
bination of both (14%). HbA1c was avail-
able in 33 of 42 women with GDM. The
group had evidence of good glycemic
control with a mean (SD) third-trimester
HbA1c level of 5.3% (0.3%) (34.9mmol/mol
[3.4 mmol/mol]). Infants with GDM
were born earlier than the control
Figure 1—Flowchart detailing infant recruitment and MR investigations.
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infants and had a lower birth weight, but
there was no statistical difference in
birth weight SD score (SDS) between
groups (Table 1). The SDS for weight,
length, and OFC were signiﬁcantly lower
in infants with GDM at the ﬁrst assess-
ment, but was similar to that of control
infants at the second assessment.
Weight gain SDS between birth and as-
sessment 2 was greater in the GDM
group. The proportions receiving exclu-
sive or predominant breast-feeding by
the second assessment were similar in
the GDM and control groups (Table 1).
At assessment 1, there were no signif-
icant differences between GDM and
control infants in unadjusted total AT
volume, AT distribution, or IHCL level
(Table 1). There were no differences in
compartmental ATvolumes (Supplemen-
tary Table 1). At assessment 2, total AT
volume was greater in infants with GDM
than in control infants (mean difference
247 cm3 [95% CI 56, 439], P = 0.01.)
There were no signiﬁcant differences in
AT distribution or in IHCL level between
groups (Table 1). Greater AT volumes
were seen in infants with GDM com-
paredwith control infants in all compart-
ments, though the differences did not
reach statistical signiﬁcance for abdomi-
nal deep subcutaneous or internal ab-
dominal compartments (Supplementary
Table 1).
After adjustment for infant size (19),
there was no signiﬁcant difference in
total AT volume between infants with
GDM and control infants at assessment
1 (Table 2). Although several AT com-
partments appeared greater in infants
with GDM, there were no statistically
signiﬁcant differences between groups
for any of the AT compartments (Supple-
mentary Table 2). At assessment 2, total
AT volume was greater in infants with
GDM (mean difference 16.0% [95% CI
6.0, 27.1], P = 0.002), and the change
in total AT volume between assess-
ments was greater in infants with GDM
compared with control infants (mean
difference); 35.8% [95% CI 11.7, 65.2],
Table 1—Maternal and infant characteristics comparing GDM and control groups
GDM group (n = 42) Control group (n = 44) P value
Maternal characteristics
Maternal prepregnancy BMI (kg/m2)* 24.2 (21.7, 30.3) 21.9 (20.3, 24.5) 0.001
Caucasian (%)† 67 86 0.09
Maternal graduate (%)† 76 77 0.91
Infant characteristics at birth
Gestation (weeks+days) 38+5 (1+1) 39+6 (1+1) ,0.001
Male sex (%)† 41 61 0.05
Weight (g) 3,440 (356) 3,632 (419) 0.02
Weight SDS 20.06 (0.77) 0.28 (0.88) 0.06
Infant anthropometrics at assessment 1
Age (days)* 11.0 (7.8, 14.3) 8.5 (2.0, 14.8) 0.22
Weight (g) 3,538 (385) 3,703 (471) 0.08
Weight SDS 20.49 (0.76) 20.12 (0.84) 0.04
Length (cm) 52.1 (1.7) 53.6 (2.4) 0.001
Length SDS 0.23 (0.88) 1.03 (1.24) 0.001
OFC (cm) 35.2 (1.2) 35.8 (1.4) 0.04
OFC SDS 20.37 (0.85) 0.11 (1.01) 0.02
Total AT volume (cm3) 961 (189) 989 (241) 0.55
Internal abdominal AT/nonabdominal superﬁcial
subcutaneous AT ratio 0.06 (0.02) 0.06 (0.02) 0.73
IHCL (CH2/H2O ratio)* 1.01 (0.55, 1.95) 0.88 (0.35, 1.75) 0.44
Infant anthropometrics at assessment 2 (n = 38) (n = 35)
Age (days)* 70.5 (67, 74) 71 (66, 74) 0.75
Weight (g) 5,755 (625) 5,695 (619) 0.68
Weight SDS 0.46 (0.93) 0.22 (0.81) 0.24
Weight gain SDS 0.62 (1.08) 0.05 (0.95) 0.02
Length (cm) 59.5 (2.1) 60.3 (1.7) 0.09
Length SDS 0.62 (0.95) 0.85 (0.91) 0.29
OFC (cm) 39.5 (1.2) 40.0 (1.1) 0.05
OFC SDS 20.11 (0.98) 0.14 (0.78) 0.22
Total AT (cm3) 2,185 (416) 1,938 (403) 0.01
Change in total AT (cm3) 1,232 (402) 968 (425) 0.01
Internal abdominal AT/nonabdominal superﬁcial
subcutaneous AT ratio 0.06 (0.02) 0.06 (0.02) 0.75
IHCL (CH2/H2O ratio)ǂ 1.92 (0.29) 1.85 (0.36) 0.85
Feeds†
Exc/pred breast fed 71 74 0.37
Mixed fed 5 9
Exc/pred formula fed 24 17
Data are reported as the mean (SD), unless otherwise indicated. P values were obtained by independent-samples t test (GDM vs. control) except
where notedQ:12 . *Values are given as the median (interquartile range), with P value obtained by Mann-Whitney U test. †Values are given as %, with
P value obtained by x2 test. ǂValues are given as the geometric mean (SD), with P value obtained by independent-samples t test after log
transformation.
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P = 0.003) (Table 2). All AT compart-
ments were greater in infants with
GDM, although the difference in the ab-
dominal deep subcutaneous compart-
ment was not statistically signiﬁcant
(Supplementary Table 2).
There was no interaction detected be-
tween maternal GDM status and infant
sex for any outcome at either assess-
ment. After adjustment for infant sex
and maternal prepregnancy BMI, the re-
sults of comparisons between infants
with GDM and control infants at the ﬁrst
and second assessments were relatively
unchanged (Table 2 and Supplementary
Table 2). Sensitivity analyses in women
with normal prepregnancy BMI and in
Caucasian infants did not signiﬁcantly
alter the results; the total AT volume at
assessment 2 remained statistically
greater in infants with GDM after adjust-
ment for potential confounders.
CONCLUSIONS
We show that adiposity in infants with
GDM appears to be ampliﬁed in early
infancy. Infants with GDM had on aver-
age 16% greater total AT volume com-
pared with control infants by 2 months
of age, despite no signiﬁcant difference
soon after birth. To the best of our
knowledge, this is a novel observation.
The increase in adiposity was not ac-
companied by altered AT distribution
or IHCL content. These conclusions re-
main robust to adjustment for mater-
nal prepregnancy BMI, supporting an
independent effect of GDM on infant
adiposity.
The strengths of our study included
the use of a direct method to accurately
quantify total and compartmental AT
volume, with adequate power to de-
tect differences likely to be clinically rel-
evant in a relatively small number of
infants. A further strength was the lon-
gitudinal design, enabling assessment of
the evolution of adiposity in early in-
fancy. Differences in total and compart-
mental AT volumes at 8–12 weeks of age
were consistent after adjustment for
confounders and in sensitivity analyses,
leading to increased conﬁdence in the
ﬁndings.
A limitation of our study was that we
did not examine for the effect of pre-
existing diabetes on offspring adiposity.
However, the metabolic effects of expo-
sure to diabetes in utero appear to be
similar regardless of diabetes type (21).
Our study was also not designed to en-
able the exploration of intrauterine and
genetic inﬂuences, but sibling compari-
son studies (3,4) strongly support an in-
trauterine effect that is independent of
genetic predisposition.
The ﬁnding of similar total AT volume
in infants with GDM and control infants
in the early newborn period contrasts
with the greater adiposity in infants of
mothers with diabetes identiﬁed in
some previous studies (7,22,23), but is
in keeping with results from two other
recent studies (24,25). It is possible that
strict maternal glucose control in our co-
hort may have attenuated any between-
group neonatal differences. An Austra-
lian study (24), using air displacement
plethysmography, reported similar body
fat percentages in the infants of mothers
with and without GDM. The authors at-
tributed this to good maternal glucose
control, with a mean third-trimester
HbA1c level for the group of 5.4%, which
is similar to that in our study. In contrast
with our study, longitudinal datawerenot
obtained. Brumbaugh et al. (25) also used
air displacement plethysmography to
measure body fat percentage, with similar
ﬁndings. In addition, the authors (25)mea-
sured two AT compartments using MRI
(deﬁned as intra-abdominal or subcutane-
ous fat), and reported similar volumes in
infants with GDM and control infants, but
acknowledged a limited power to detect
differences. Our results corroborate these
ﬁndings of similar AT distribution in an ad-
equately powered cohort. Intriguingly, and
in contrastwithourownstudy,Brumbaugh
et al. (25) found IHCL levels to be greater
in infants of mothers with GDM. However,
they estimated IHCL levels without ad-
justment for intrahepatic water and
studied only 20 infants. The treatment
of maternal GDM and glycemic control
were not described, and exploration of
the relative inﬂuences of maternal GDM
and obesity was not possible because all
mothers with GDM were obese (pre-
pregnancy BMI .30 kg/m2) (25). The
differences they report in IHCL levels
may relate tomaternal obesity, because
maternal BMI is positively correlated
with IHCL level in infants (20).
The International Association of Dia-
betes and Pregnancy Study Groups
proposed new criteria for universal
screening for maternal GDM in 2010
(26). In a large Spanish study, these cri-
teria resulted in signiﬁcantly improved
pregnancy outcomes, including a reduced
risk of large for gestational age infants
(27). Two randomized controlled trials
Table 2—Adjusted percentage differences in total AT, AT distribution, and IHCL level for infants with GDM compared
with control infants
Outcomes
Model 1 Model 2
Difference (%) 95% CI P value Difference (%) 95% CI P value
Assessment 1
Total AT 6.9 21.4, 15.9 0.11 5.4 23.6, 15.6 0.24
Internal abdominal AT/nonabdominal
superﬁcial subcutaneous AT ratio 1.2 211.3, 15.6 0.86
IHCL*
Assessment 2
Total AT 16.0 6.0, 27.1 0.002 12.5 1.0, 25.0 0.03
Change in total AT 35.8 11.7, 65.2 0.003 32.4 5.2, 66.3 0.02
Internal abdominal AT/nonabdominal
superﬁcial subcutaneous AT ratio 20.2 215.1, 17.2 0.98
IHCL 5.7 230.2, 59.6 0.79 3.5 235.4, 65.6 0.89
Model 1, adjustment of AT for body size using indices (18) (not applicable for AT ratios), and IHCL for postnatal age; Model 2, same as model 1
plus adjustment for infant sex and maternal prepregnancy BMI. *Non-normal distribution, and therefore the percentage difference, was not
calculable.
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demonstrated reduced birth weight (28)
and neonatal fat mass (29) with treat-
ment of mild GDM. Although differences
may exist in our study population and the
criteria used to diagnose GDM, our ﬁnd-
ings support the concept that more strin-
gent screening and treatment strategies
for GDMmay attenuate the differences in
adiposity between infants of mothers
with GDM and those without GDM at
birth. Of note, there is evidence that ben-
eﬁtsmay not persist beyond the newborn
period as follow-up studies (30,31) have
not shown a reduction in early childhood
obesity with treatment. The later devel-
opment of obesity in childhood might be
considered to be due to exposure to an
obesogenic environment rather than to a
direct effect of maternal diabetes; how-
ever, our study suggests that this is un-
likely to be the case because differences
in adiposity between GDM and control
infants emerge early in infancy during
the period of breast-feeding.
We identiﬁed a striking difference in
total AT volume in infants with GDM
compared with control infants by 10
weeks. This was particularly notable be-
cause greater adiposity was not accom-
panied by discernible differences in
body weight or length, although infants
with GDM demonstrated rapid weight
gain, which is itself a risk for greater ad-
iposity in childhood (32). This appeared
to occur as a result of greater AT depo-
sition. Our study was not powered to
detect small differences in regional AT
compartments, and it is possible that
GDM infants had subtle differences in
AT from birth, which may have evolved
in early infancy. What is remarkable is
the extent to which total AT differed by
the second assessment. The mecha-
nisms that lead to increased adiposity
in infants with GDM in early infancy
merit consideration. One possible expla-
nation is that intrauterine or neonatal
exposure to an excess of nutrients may
alter hypothalamic sensing, leading to
alterations in satiety and appetite
(33,34). Another potential mechanism
for the differences described, concerns
differences in breast milk composition.
The proportion of breast-fed infants in
our study was similar in both groups. It
has been suggested (35) that neonatal
ingestion of breast milk from mothers
with diabetes may increase the risk of
overweight in early childhood. BreastQ:9
milk alterations, including higher glucose
concentration, have been demonstrated
in mothers with type 1 diabetes, which
may inﬂuence infant body composition
(36,37). The exploration of breast milk
composition in mothers with GDM has
been limited, and an examination of the
relationship among GDM status, breast
milk composition, and infant adiposity
may provide further insight.
The relative contributions of mater-
nal BMI and diabetes on offspring adi-
posity remain uncertain (4,5). The HAPO
group found that both maternal GDM
(diagnosed post hoc using International
Association of Diabetes and Pregnancy
Study Groups criteria) and, to a lesser
extent, maternal obesity are indepen-
dently associated with newborn adipos-
ity, and that their combination has a
greater impact than either alone (38).
We found that differences in adiposity
between GDM and control groups at 10
weeks were slightly attenuated after ad-
justment for maternal prepregnancy
BMI. Our ﬁndings support an indepen-
dent effect of maternal GDM on infant
adiposity, with a lesser contribution
from maternal prepregnancy BMI.
In conclusion, in this contemporary
predominantly breast-fed cohort with
good glycemic control in pregnancy,
we demonstrate that infants with GDM
have signiﬁcantly greater total AT vol-
ume at 2–3 months of age compared
with control infants. This is particularly
striking given that there was no signiﬁ-
cant difference in total adiposity at
birth. This indicates, ﬁrst, that careful
control of GDM may not be sufﬁcient
to ameliorate the effects of maternal
GDM on later infant health and, second,
that this may be mediated by excess ad-
iposity. Because adiposity appears to
track from infancy into childhood (39),
this is a plausible harbinger of longer-
term risks to health. We suggest that a
key research priority is to examine the
evolution of early infancy adiposity into
childhood and the potential effects on
metabolic health in the offspring of
mothers with GDM. Reduction in post-
natal adiposity may be a therapeutic tar-
get to break the cycle of increasing
population obesity and related compli-
cations, including type 2 diabetes.
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